Literature DB >> 12781076

Targeted therapy for lung cancer.

Rajesh Kukunoor1, Jigar Shah, Tarek Mekhail.   

Abstract

Lung cancer remains the leading cause of death in men and women in the United States. This status is attributed to late diagnosis and lack of effective chemotherapy for metastatic lung cancer. Understanding of the mechanism by which mutated genes confer a neoplastic phenotype on cells has resulted in the development of many potential targeted cancer therapies. This article briefly discusses the work being done with some of these targeted agents in the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781076     DOI: 10.1007/s11912-003-0075-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  55 in total

1.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

Authors:  F R Khuri; J R Rigas; R A Figlin; R J Gralla; D M Shin; R Munden; N Fox; M R Huyghe; Y Kean; S D Reich; W K Hong
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

Review 2.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

3.  Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Authors:  E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; X Jing ; M Roberge; E Fuse; T Kuwabara; A M Senderowicz
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

Authors:  A F Soriano; B Helfrich; D C Chan; L E Heasley; P A Bunn; T C Chou
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

5.  Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.

Authors:  S C Grant; M G Kris; A N Houghton; P B Chapman
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

6.  Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.

Authors:  Frances A Shepherd; Giuseppe Giaccone; Lesley Seymour; Channa Debruyne; Andrea Bezjak; Vera Hirsh; Michael Smylie; Sheldon Rubin; Heidi Martins; Alan Lamont; Maciej Krzakowski; Anna Sadura; Benny Zee
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

Review 7.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

Authors:  X D Yang; X C Jia; J R Corvalan; P Wang; C G Davis
Journal:  Crit Rev Oncol Hematol       Date:  2001-04       Impact factor: 6.312

8.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

9.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

Review 10.  Potent and specific inhibitors of protein kinase C of microbial origin.

Authors:  T Tamaoki; H Nakano
Journal:  Biotechnology (N Y)       Date:  1990-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.